116 related articles for article (PubMed ID: 38679992)
1. The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial.
Rizky D; Tandarto K; Pangarsa EA; Naibaho RM; Kurniawan SP; Santosa D; Setiawan B; Suharti C
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1315-1324. PubMed ID: 38679992
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
3. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Evens AM; Sehn LH; Farinha P; Nelson BP; Raji A; Lu Y; Brakman A; Parimi V; Winter JN; Schumacker PT; Gascoyne RD; Gordon LI
J Clin Oncol; 2010 Feb; 28(6):1017-24. PubMed ID: 20048181
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
Hashimoto Y; Yokohama A; Saitoh A; Nakahashi H; Toyama K; Mitsui T; Koiso H; Saitoh T; Handa H; Uchiumi H; Jinbo T; Murayama K; Matsumoto M; Sawamura M; Karasawa M; Murakami H; Hirato J; Nojima Y; Kojima M; Tsukamoto N
J Clin Exp Hematop; 2013; 53(3):197-205. PubMed ID: 24369221
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Janik JE; Morris JC; Pittaluga S; McDonald K; Raffeld M; Jaffe ES; Grant N; Gutierrez M; Waldmann TA; Wilson WH
Blood; 2004 Nov; 104(10):3355-7. PubMed ID: 15205267
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
10. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].
Lu GQ; Zhou XH; Chen H; Tan JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):733-7. PubMed ID: 27342500
[TBL] [Abstract][Full Text] [Related]
11. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Tomita N; Suzuki T; Miyashita K; Yamamoto W; Motohashi K; Tachibana T; Takasaki H; Kawasaki R; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Taguchi J; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Motomura S; Kawamoto K; Sone H; Takizawa J
Leuk Lymphoma; 2016 Dec; 57(12):2763-2770. PubMed ID: 27320054
[TBL] [Abstract][Full Text] [Related]
12. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
15. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
16. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
19. The expression of hypoxia inducible factor-1 alpha in diffuse large B-cell lymphoma (DLBCL) patients: a cross-sectional study in Indonesia.
Pangarsa EA; Rizky D; Tandarto K; Naibaho RM; Kurniawan SP; Istiadi H; Puspasari D; Santoso AG; Setiawan B; Santosa D; Haryana SM; Suharti C
Ann Med Surg (Lond); 2023 Oct; 85(10):4780-4787. PubMed ID: 37811023
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma.
Hu X; Zeng M; Yang SE; Liang X; Ding SS; Guo L; Li S; Wen SJ
Medicine (Baltimore); 2017 Nov; 96(45):e8494. PubMed ID: 29137041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
